![Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram](https://www.researchgate.net/publication/342628025/figure/fig2/AS:908830661697536@1593693523052/Kaplan-Meier-curves-for-overall-survival-OS-overall-survival-non-MDT-non.png)
Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram
![A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy | Journal for ImmunoTherapy of Cancer | Full Text A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy | Journal for ImmunoTherapy of Cancer | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40425-018-0418-7/MediaObjects/40425_2018_418_Fig3_HTML.png)
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy | Journal for ImmunoTherapy of Cancer | Full Text
![Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram](https://www.researchgate.net/publication/333294637/figure/fig2/AS:761410896277505@1558545912697/Kaplan-Meier-curve-showing-the-overall-survival-OS-of-the-patient-cohort-grouped-by.png)
Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00268-019-05071-2/MediaObjects/268_2019_5071_Fig3_HTML.png)
Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink
![A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram](https://www.researchgate.net/profile/Richard-Stephens-3/publication/5503862/figure/fig2/AS:667207130423307@1536085984764/A-Overall-survival-OS-in-elderly-patients-70-years-in-relation-to-treatment-arm.png)
A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
![Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-018-0061-6/MediaObjects/41416_2018_61_Fig1_HTML.jpg)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
![Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2468294220301076-gr1.jpg)
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
![A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine](https://www.thelancet.com/cms/attachment/4c56dec5-310c-4e24-ab78-fbf95f7c8023/gr1.jpg)
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
![The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ). The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).](https://s3-eu-west-1.amazonaws.com/ppreviews-plos-725668748/5038006/preview.jpg)
The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).
![Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0805-y/MediaObjects/41416_2020_805_Fig1_HTML.png)
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
![PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo](https://og.oa.mg/Progression%20Free%20Survival%20(PFS)%20and%20Overall%20Survival%20(OS)%20in%20Patients%20Receiving%203%20Targeted%20Therapies%20(TTS)%20for%20Metastatic%20Renal-Cell%20Carcinoma%20(MRCC).png?author=%20Roberto%20Iacovelli,%20Matteo%20Santoni,%20G.%20Di%20Lorenzo,%20L.%20Cerbone,%20Massimo%20Aglietta,%20Cristina%20Masini,%20Maria%20Olga%20Giganti,%20Caterina%20Messina,%20Cora%20N.%20Sternberg,%20G.%20Procopio)
PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo
![Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420397969-gr2.jpg)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
![Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy](https://abstracts.mirrorsmed.org/sites/default/files/908-0.jpg)
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy
![Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/4/e002114/F2.large.jpg)